Trial Profile
A Randomized Phase II Study of Clofarabine / Intermediate-Dose Cytarabine (CLARA)Versus High-Dose Cytarabine (HDAC) as Consolidation in Younger Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Cytarabine (Primary) ; Granulocyte colony-stimulating factors
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms CLARA
- 01 Sep 2020 Results (n=656) showing ELN 2017, NPM1 MRD and the KB algorithm can be integrated to refine HSCT indication in AML published in the Blood
- 21 Jun 2020 Results, pooled analysis of data from two studies (ALFA-0702 and ALFA-1200) assessing prognostic significance of concurrent gene mutations, presented at the 25th Congress of the European Haematology Association
- 06 Nov 2019 Results assessing prognostic significance of concurrent gene mutations in the patients from ALFA-0702 (NCT00932412) and older ALFA-1200 (NCT01966497) ,released in the 61st Annual Meeting and Exposition of the American Society of Hematology.